Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.52 |
| ▸ | ALDH5A1 | P51649 | 3/20 | 0.47 |
| ▸ | ABAT | P80404 | 3/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190410 | 0.82 | KDM4E (0.64) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| SCHEMBL29713168 | 0.82 | KDM4E (0.64) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| SCHEMBL29610150 | 0.78 | ALDH1A3 (0.52) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| SCHEMBL870202 | 0.78 | ALDH1A3 (0.52) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL9512877 | 0.78 | KDM4E (1.00) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL29349539 | 0.78 | KDM4E (1.00) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| Protocatechualdehyde SCHEMBL36350 | 0.78 | KDM4E (1.00) | KDM4EPTGS2RAB9AALDH1A1AOX1 | |
| SCHEMBL17058724 | 0.78 | KDM4E (0.53) | KDM4EPTGS2RAB9AAKR1C3AKR1C2 | |
| SCHEMBL9305646 | 0.77 | AKR1C3 (0.53) | KDM4EPTGS2RAB9AAKR1C3AKR1C2 | |
| Protocatechualdehyde SCHEMBL4072910 | 0.76 | KDM4E (0.95) | KDM4EPTGS2RAB9AALDH1A1AOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0488860-B1 | Method for the production of polyalkoxylated aromatic compounds | RHONE POULENC CHIMIE (FR) | 1995-10-11 | — | — | EP | claimed |
| EP-0423010-B1 | METHOD FOR THE PRODUCTION OF ALKOXYBENZALDEHYDES | RHONE-POULENC CHIMIE (FR) | 1993-09-29 | — | — | EP | claimed |
| EP-4613749-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2025-09-10 | — | — | EP | disclosed |
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-06-05 | — | — | US | disclosed |
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-15 | — | — | US | disclosed |
| US-20250145566-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2025-05-08 | — | — | US | disclosed |
| CN-119798221-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| WO-2025036275-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2025-02-20 | — | — | WO | disclosed |
| CN-119462517-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2017191098-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017191098-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-09 | — | — | WO | disclosed |
| EP-2763986-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2017-06-07 | — | — | EP | disclosed |
| CN-104017008-A | Boron-containing small molecules | ANACOR PHARMACEUTICALS INC | 2014-09-03 | — | — | CN | disclosed |
| CN-102105462-B | Amidophenoxyindazoles useful as inhibitors of C-MET | LILLY CO ELI | 2014-07-23 | — | — | CN | disclosed |
| US-6759559-B2 | HYDROGENATION CATALYST COMPLEX | DEGUSSA AG (DE) | 2004-07-06 | — | — | US | disclosed |
| US-20020016513-A1 | Use of molecular weight-enlarged catalysts in a process for asymmetric, continous hydrogenation, novel molecular weight-enlarged ligands and catalysts | DEGUSSA-HUELS AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| EP-1120162-A2 | Use of catalysts with a higher molecular weight in an asymmetrical continous hydration reaction, ligands and catalysts | Degussa AG (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-4394496-A | POLYEPOXEDES WITH GOOD HIGH TEMPERATURE PROPERTIES | THE DOW CHEMICAL COMPANY (US) | 1983-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016513-A1 | Use of molecular weight-enlarged catalysts in a process for asymmetric, continous hydrogenation, novel molecular weight-enlarged ligands and catalysts | PCNA, DNMT1, STOM | KDM4E 1445/4885PTGS2 2110/4885RAB9A 4285/4885 |
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | NLRP3, NLRP1, PYCARD | KDM4E 4454/4885PTGS2 904/4885RAB9A 3379/4885 |
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ESR1, ESR2, ESRRA | KDM4E 598/4885PTGS2 1756/4885RAB9A 2513/4885 |
| US-20250084092-A1 | ANNULATED PYRIDAZINE COMPOUND | NLRP3, NLRP1, PYCARD | KDM4E 2148/4885PTGS2 651/4885RAB9A 4216/4885 |
| US-20250145566-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | PNMT, HTR7, HTR2C | KDM4E 2129/4885PTGS2 1002/4885RAB9A 1834/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | KDM4E 2438/4885PTGS2 142/4885RAB9A 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.